Literature DB >> 10885422

MEKC of desmosine and isodesmosine in urine of chronic destructive lung disease patients.

S Viglio1, P Iadarola, A Lupi, R Trisolini, C Tinelli, B Balbi, V Grassi, D Worlitzsch, G Döring, F Meloni, K C Meyer, L Dowson, S L Hill, R A Stockley, M Luisetti.   

Abstract

Degradation of extracellular matrix components is central to many pathological features of chronic destructive lung disorders. Desmosine and isodesmosine are elastin-derived cross-linked amino acids whose urine levels are considered representative of elastin breakdown. The aim of this study was to apply a novel methodology, based on high-performance capillary electrophoresis, to the quantification of desmosine and isodesmosine in 11 patients with stable chronic obstructive pulmonary disease (COPD), 10 with an exacerbation of COPD, nine with alpha1-antitrypsin deficiency, 13 with bronchiectasis, and 11 adults with cystic fibrosis, in comparison to 24 controls. It was found that, in patients with stable COPD, urinary desmosine levels were higher than in controls (p=0.03), but lower than in COPD subjects with an exacerbation (p< or =0.05). The highest desmosine levels were found in subjects with alpha1-antitrypsin deficiency, bronchiectasis and cystic fibrosis (p<0.001 versus stable COPD). In a short-term longitudinal study, five stable COPD patients showed a constant rate of desmosine excretion (mean coefficient of variation <8% over three consecutive days). In conclusion, the present method is simple and suitable for the determination of elastin-derived cross-linked amino acid excretion in urine, giving results similar to those obtained using other separation methods. In addition, evidence is presented that urinary desmosine excretion is increased in conditions characterized by airway inflammation, such as exacerbations of chronic obstructive pulmonary disease, bronchiectasis and cystic fibrosis. Results obtained in subjects with alphal-antitrypsin deficiency suggest that this method might be used to evaluate the putative efficacy of replacement therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10885422     DOI: 10.1034/j.1399-3003.2000.01511.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  19 in total

Review 1.  COPD exacerbations . 2: aetiology.

Authors:  E Sapey; R A Stockley
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

2.  Alveolar inflammation in cystic fibrosis.

Authors:  Martina Ulrich; Dieter Worlitzsch; Simona Viglio; Nanna Siegmann; Paolo Iadarola; Janis K Shute; Marianne Geiser; Gerald B Pier; Godehard Friedel; Mark L Barr; Antje Schuster; Keith C Meyer; Felix Ratjen; Thomas Bjarnsholt; Erich Gulbins; Gerd Döring
Journal:  J Cyst Fibros       Date:  2010-03-29       Impact factor: 5.482

3.  Quantification of desmosine and isodesmosine using MALDI-ion trap tandem mass spectrometry.

Authors:  Pratikkumar Rathod; Manjeet Kaur; Hsin-Pin Ho; Marissa E Louis; Basant Dhital; Philip Durlik; Gregory S Boutis; Kevin J Mark; Jong I Lee; Emmanuel J Chang
Journal:  Anal Bioanal Chem       Date:  2018-07-31       Impact factor: 4.142

4.  Urinary desmosine: a biomarker of structural lung injury during CF pulmonary exacerbation.

Authors:  Theresa A Laguna; Brandie D Wagner; Barry Starcher; Heidi K Luckey Tarro; Shelley A Mann; Scott D Sagel; Frank J Accurso
Journal:  Pediatr Pulmonol       Date:  2012-03-19

5.  Free Urinary Desmosine and Isodesmosine as COPD Biomarkers: The Relevance of Confounding Factors.

Authors:  Sara Ongay; Marijke Sikma; Peter Horvatovich; Jos Hermans; Bruce E Miller; Nick H T Ten Hacken; Rainer Bischoff
Journal:  Chronic Obstr Pulm Dis       Date:  2016-03-01

6.  Association between markers of emphysema and more severe chronic obstructive pulmonary disease.

Authors:  P Boschetto; S Quintavalle; E Zeni; S Leprotti; A Potena; L Ballerin; A Papi; G Palladini; M Luisetti; L Annovazzi; P Iadarola; E De Rosa; L M Fabbri; C E Mapp
Journal:  Thorax       Date:  2006-06-12       Impact factor: 9.139

7.  Therapeutic effects of hyaluronan on smoke-induced elastic fiber injury: does delayed treatment affect efficacy?

Authors:  Jerome O Cantor; Joseph M Cerreta; Marcos Ochoa; Shuren Ma; Ming Liu; Gerard M Turino
Journal:  Lung       Date:  2010-12-14       Impact factor: 2.584

8.  High-sensitivity nanoLC-MS/MS analysis of urinary desmosine and isodesmosine.

Authors:  Michel Boutin; Carl Berthelette; François G Gervais; Mary-Beth Scholand; John Hoidal; Mark F Leppert; Kevin P Bateman; Pierre Thibault
Journal:  Anal Chem       Date:  2009-03-01       Impact factor: 6.986

9.  Impact of delivery mode of hyaluronan oligomers on elastogenic responses of adult vascular smooth muscle cells.

Authors:  B Joddar; S Ibrahim; A Ramamurthi
Journal:  Biomaterials       Date:  2007-06-14       Impact factor: 12.479

10.  The detection and quantitation of free desmosine and isodesmosine in human urine and their peptide-bound forms in sputum.

Authors:  Shuren Ma; Seymour Lieberman; Gerard M Turino; Yong Y Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-16       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.